首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >Power and Sample Size Calculations in Clinical Trials with Patient-Reported Outcomes under Equal and Unequal Group Sizes Based on Graded Response Model: A Simulation Study
【24h】

Power and Sample Size Calculations in Clinical Trials with Patient-Reported Outcomes under Equal and Unequal Group Sizes Based on Graded Response Model: A Simulation Study

机译:基于分级响应模型的等量和不等组规模患者报告结果的临床试验的功效和样本量计算:模拟研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: To provide a valid sample size strategy based on simulation and to evaluate the statistical power in clinical trials with patient-reported outcomes (PROs) based on a polytomous item response theory model the graded response model (GRM) and to compare this framework with the classical test theory (CTT) approach. Methods: One thousand randomized clinical trials were simulated using PRO based on the GRM and under various combinations of the number of patients in each arm, the group allocation ratio, the number of items and categories, and group effects. The power and sample size estimated in the simulations were then compared with those computed using the CTT framework. Results: The results indicated that the impact of the most influential factors, including the number of patients, group allocation ratio, group effects, and the number of categories, on the power and sample size of the GRM-based and CTT-based approaches was similar. Nevertheless, the strong impact of the number of items on these issues distinguished the two approaches. Conclusions: It is crucial to use an adapted sample size formula in a GRM-based analysis because the classical formula designed for the CTT-based approach does not consider the impact of the number of items, which could result in an inadequately sized study and a decrease in power. Thus, when clinicians design a randomized clinical trial with polytomous PRO endpoints using classical sample size formula as the base, they should be aware of the possibility of making an incorrect clinical decision.
机译:目的:提供基于模拟的有效样本量策略,并基于多项目项反应理论模型,分级反应模型(GRM)评估具有患者报告结果(PRO)的临床试验中的统计功效,并将此框架与经典测试理论(CTT)方法。方法:使用PRO基于GRM并在各组患者数,组分配比例,项目和类别数以及组效果的各种组合下,使用PRO模拟了1000项随机临床试验。然后将模拟中估计的功效和样本数量与使用CTT框架计算出的功效和样本数量进行比较。结果:结果表明,最有影响力的因素,包括患者人数,组分配比例,组效应和类别数量,对基于GRM和基于CTT的方法的功效和样本量的影响为类似。但是,项目数量对这些问题的强烈影响使这两种方法区别开来。结论:在基于GRM的分析中使用经过调整的样本量公式非常重要,因为为基于CTT的方法设计的经典公式并未考虑项目数量的影响,这可能会导致研究规模不足,功率降低。因此,当临床医生使用经典的样本量公式作为基础设计具有多义PRO终点的随机临床试验时,他们应该意识到做出错误临床决定的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号